Breast Cancer Research - Penn State Cancer Institute
Breast Cancer Research
Research into breast cancer at Penn State Cancer Institute is conducted by a dedicated breast cancer team. See current clinical trials and members of that team here.
Clinical Trials
CUFF Study: Characterization of Upper Limb Function following Mastectomy and Reconstruction for Breast Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
S1501, Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Pilot study to evaluate if contrast-enhanced ultrasound (CEUS) can predict treatment response in triple negative breast cancer (TNBC) patients receiving combined chemotherapy and Immune Checkpoint Inhibitors (ICI).
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY
NRG-BR007: A Phase III Clinical Trial Evaluating Deescalation of Breast Radiation for Conservative Treatment of Stage I, Hormone sensitive, HER2- Negative Oncotype recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A Phase II Study of Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study) (HCRN-BRE20-468)
CCTG MA.39:Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Attitudes towards cannabis use in the PSCI cancer population
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in Triple Positive Breast Cancers
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score (OFSET)
Patient and Provider Preferences for Breast Cancer Treatment Side Effect Prediction
A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
BINGO: Bridging Knowledge, Increasing Awareness - Empowering the Black Community through Educational Gamification on Cancer Screenings and Clinical Trial Diversity
NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PI3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Alison | Chetlen | DO | ||
 |
Daleela | Dodge | MD | ||
 |
Claudia | Kasales | MD | ||
 |
Rena | Kass | MD | ||
 |
Julie | Mack | MD | ||
 |
John | Potochny | MD | ||
 |
Rebecca | Sivarajah | MD | ||
 |
Cristina | Truica | MD | ||
 |
Kristine | Widders | MD |
Research into breast cancer at Penn State Cancer Institute is conducted by a dedicated breast cancer team. See current clinical trials and members of that team here.
CUFF Study: Characterization of Upper Limb Function following Mastectomy and Reconstruction for Breast Cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
S1501, Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Pilot study to evaluate if contrast-enhanced ultrasound (CEUS) can predict treatment response in triple negative breast cancer (TNBC) patients receiving combined chemotherapy and Immune Checkpoint Inhibitors (ICI).
Prospective evaluation of potential effects of repeated gadoliniumbased contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group ODYSSEY
NRG-BR007: A Phase III Clinical Trial Evaluating Deescalation of Breast Radiation for Conservative Treatment of Stage I, Hormone sensitive, HER2- Negative Oncotype recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A Phase II Study of Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study) (HCRN-BRE20-468)
CCTG MA.39:Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Attitudes towards cannabis use in the PSCI cancer population
An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in Triple Positive Breast Cancers
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score (OFSET)
Patient and Provider Preferences for Breast Cancer Treatment Side Effect Prediction
A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
BINGO: Bridging Knowledge, Increasing Awareness - Empowering the Black Community through Educational Gamification on Cancer Screenings and Clinical Trial Diversity
NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PI3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Alison | Chetlen | DO | ||
|
Daleela | Dodge | MD | ||
|
Claudia | Kasales | MD | ||
|
Rena | Kass | MD | ||
|
Julie | Mack | MD | ||
|
John | Potochny | MD | ||
|
Rebecca | Sivarajah | MD | ||
|
Cristina | Truica | MD | ||
|
Kristine | Widders | MD |